Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL

Inclusion Criteria

• •Histologically confirmed diagnosis of diffuse large B cell or mantle cell Non-Hodgkin's Lymphoma with characteristic immunophenotypic profiles. For mantle cell: CD5(+), CD19(+) or CD20(+), cyclin D1(+), CD23(-) and CD10(-).
• •Patient has not received any prior anti-cancer therapy for lymphoma
• •Tumor tissue confirmed to express the CD20 antigen
• •Available frozen tumor tissue(rebiopsy if needed)
• •Patient has measurable disease as defined by a tumor mass \> 1.5 cm
• •Patient has Stage II, III, or IV disease
• •Age \> 18 years
• •Absolute granulocyte count \> 1000 cells/mm3
• •Platelet count \> 50,000 cells/mm3
• •Creatinine \< 2.0 x ULN
• •Total bilirubin \< 2.0 x ULN